Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer

Table 5 Univariate Cox regression analysis for clinicopathological features and genotype

Variable	PFS			OS
	HR	95%CI	P value	HR	95%CI	P value
KRAS mutated	1.390	0.895-2.164	0.142	1.669	0.996-2.797	0.052
BRAF V600E	0.884	0.356-2.196	0.791	1.514	0.545-4.207	0.426
LOH	1.013	0.632-1.624	0.957	1.020	0.592-1.758	0.944
TYMS 5’UTR			0.561			0.845
2R	1.000			1.000
2R/3R	1.243	0.616-2.508	0.543	1.276	0.556-2.928	0.565
3R	0.974	0.474-2.003	0.944	1.239	0.535-2.870	0.616
TYMS 5’UTR			0.887			0.486
2RG	1.000			1.000
2RG/3RC	1.151	0.535-2.475	0.720	0.978	0.388-2.468	0.963
2RG/3RG	1.351	0.625-2.921	0.444	1.688	0.689-4.132	0.252
3RC	1.038	0.428-2.517	0.935	0.876	0.293-2.620	0.813
3RG/3RC	0.883	0.391-1.995	0.764	1.648	0.660-4.113	0.284
3RG	1.107	0.433-2.832	0.832	1.054	0.348-3.189	0.926
TYMS 5’UTR			0.726			0.562
2R	1.000			1.000
2RG/3RC	1.864	0.738-4.713	0.188	1.678	0.546-5.160	0.366
2RG/3RCLOH	0.783	0.300-2.044	0.617	1.044	0.328-3.323	0.942
2RG/3RG	1.058	0.372-3.014	0.916	1.869	0.537-6.504	0.325
2RG/3RGLOH	1.936	0.630-5.948	0.248	3.875	1.019-14.740	0.047
2RGLOH/3RC	1.155	0.301-4.441	0.834	1.091	0.126-9.412	0.937
2RGLOH/3RG	1.656	0.617-4.442	0.317	1.745	0.546-5.576	0.348
3RC	1.096	0.428-2.806	0.848	1.070	0.325-3.521	0.912
3RG	1.163	0.432-3.134	0.765	1.281	0.385-4.270	0.687
3RG/3RC	1.001	0.413-2.426	0.998	2.144	0.758-6.064	0.151
TYMS 5’UTR groups			0.812			0.489
Low expression	1.063	0.633-1.784	0.818	0.696	0.384-1.261	0.232
Medium expression	0.888	0.518-1.523	0.667	0.851	0.460-1.572	0.606
High expression	1.000			1.000
TYMS 3’UTR			0.295			0.340
del/del	0.602	0.305-1.190	0.144	0.563	0.259-1.224	0.147
ins/del	0.764	0.475-1.228	0.267	0.910	0.522-1.587	0.739
ins/ins	1.000			1.000
TYMS 3’UTR			0.067		1	0.095
del/del	0.421	0.194-0.912	0.028	0.311	0.125-0.772	0.012
del/LOH	0.784	0.263-2.334	0.662	0.773	0.175-3.417	0.734
ins/del	0.438	0.240-0.802	0.007	0.459	0.230-0.918	0.028
ins/LOH	0.516	0.274-0.973	0.041	0.488	0.233-1.020	0.057
ins/ins	1.000			1.000
TYMS 3’UTR groups			0.225			0.187
Low expression	0.639	0.323-1.263	0.198	0.503	0.230-1.102	0.086
Medium expression	0.435	0.435-1.118	0.135	0.738	0.426-1.279	0.279
High expression	1.000			1.000

CT: Chemotherapy; LOH: Loss of heterozygosity; OS: Overall survival; PFS: Progression-free survival; UTR: Untranslated region.